KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Receivables for 16 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 39.93% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, down 39.93% year-over-year, with the annual reading at $1.4 million for FY2025, 39.93% down from the prior year.
  • Receivables hit $1.4 million in Q4 2025 for Arbutus Biopharma, up from $905000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $2.7 million in Q1 2023 to a low of $899000.0 in Q4 2021.
  • Historically, Receivables has averaged $1.7 million across 5 years, with a median of $1.6 million in 2021.
  • Biggest five-year swings in Receivables: skyrocketed 102.89% in 2023 and later crashed 44.74% in 2025.
  • Year by year, Receivables stood at $899000.0 in 2021, then surged by 50.39% to $1.4 million in 2022, then surged by 31.36% to $1.8 million in 2023, then skyrocketed by 35.64% to $2.4 million in 2024, then plummeted by 39.93% to $1.4 million in 2025.
  • Business Quant data shows Receivables for ABUS at $1.4 million in Q4 2025, $905000.0 in Q3 2025, and $1.0 million in Q2 2025.